Top U.S. Healthcare Institution Deploys DarioHealth's Full Suite, Contributing to 2025 Revenue Growth and Market Expansion
Rhea-AI Summary
DarioHealth (NASDAQ: DRIO) has secured a partnership with a major U.S. healthcare research and medical institution, marking its second significant healthcare employer agreement. The partnership, which is already generating recurring revenue in 2025, involves the implementation of Dario's complete suite of AI-powered digital health solutions.
The institution will deploy Dario Health, Dario Mind, and Dario Move platforms, covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company's solutions have demonstrated above-average engagement rates and significant improvements in health metrics, including reductions in A1c, blood pressure, and MSK-related pain.
Positive
- Already generating recurring revenue in 2025
- Second major healthcare employer partnership secured
- Full suite deployment demonstrates strong product adoption
- Above-industry-average engagement rates
- Proven clinical outcomes in multiple health metrics
Negative
- None.
News Market Reaction
On the day this news was published, DRIO declined 1.61%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Second major healthcare employer signs with DarioHealth, accelerating growth in 2025 and reinforcing its leadership in AI-powered, clinically validated digital health solutions for chronic condition management

Chosen for its proven impact, personalization, and seamless integration, Dario's AI-driven platform will provide employees with data-driven support through its full suite of solutions—Dario Health, Dario Mind, and Dario Move—spanning multiple chronic conditions, including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
"In today's competitive benefits landscape, employers are demanding solutions that deliver real-world results — not just promises," said Steven Nelson, Chief Commercial Officer of DarioHealth. "We believe this partnership sends a strong signal that leading organizations are moving beyond generic wellness apps and toward data-driven platforms that scale quickly and demonstrate clinical, financial, and cultural ROI. Dario is proving that we're not only easy to deploy, but powerful enough to meet the performance standards of the most demanding enterprise workforces in the country."
The newly added employer is a nationally strategic institution with a central role in
Dario's momentum in the employer space continues to build, with engagement rates well above industry averages and early outcomes showing significant reductions in A1c, blood pressure, and MSK-related pain—alongside measurable improvements in mental well-being. The agreement provides further market validation of Dario's approach as a scalable, clinically integrated solution. As digital health adoption accelerates, Dario believes that partnerships with leading healthcare systems will be a key marker of trust and reliability in the sector.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care, and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expectation that the agreement will generate recurring revenue in 2025, its belief that Dario's AI-driven platform will provide employees with data-driven support through its full suite of solutions, the forecast that leading organizations are moving beyond generic wellness apps and toward data-driven platforms, its belief that the Dario platform is powerful enough to meet the performance standards of the most demanding enterprise workforces in the country, that Dario's momentum in the employer space continues to build, and its belief that partnerships with leading healthcare systems will be a key marker of trust and reliability in the sector. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the
DarioHealth Corporate Contact:
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact:
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/top-us-healthcare-institution-deploys-dariohealths-full-suite-contributing-to-2025-revenue-growth-and-market-expansion-302423158.html
SOURCE DarioHealth Corp.